12:00 AM
 | 
Dec 18, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZYC101a: Began Phase II trial

Zycos Inc., Lexington, Mass.
Product: ZYC101a
Business: Cancer, Infectious diseases
Therapeutic category: Viral infection, Immune stimulation
Target: Immune cells...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >